Skip to main content
Fig. 1 | Journal for Immunotherapy of Cancer

Fig. 1

From: Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

Fig. 1

Cellular immune responses to CV9103. Evaluation of antigen-specific cellular immune responses as measured ex vivo by ELISpot, ICS and tetramer staining. Shown is percentage of patients responding against ≥ one antigen at ≥ one time point within evaluable patients (n = 33). Percentages of responding patients are indicated for patients eliciting a CD4 response, a CD8 response, both CD4 and CD8 responses and either CD4 or CD8 responses. Tetramer binding was measured only in HLA-A2+ patients (n = 14)

Back to article page